Marker Therapeutics, Inc.

NasdaqCM:MRKR Stock Report

Market Cap: US$30.2m

Marker Therapeutics Past Earnings Performance

Past criteria checks 0/6

Marker Therapeutics has been growing earnings at an average annual rate of 33.4%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 49% per year.

Key information

33.4%

Earnings growth rate

49.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate49.0%
Return on equity-129.3%
Net Margin-178.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Oct 04
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Sep 13

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Aug 11

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Jun 17
Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Mar 04
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Nov 19
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics: Passing Through A Catalyst Desert

Oct 22

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Aug 17
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

May 04
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Feb 22
Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Marker shares rise as it completes construction of its cGMP manufacturing facility

Jan 13

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Jan 05

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Dec 29
Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Marker Therapeutics EPS misses by $0.02

Nov 09

Revenue & Expenses Breakdown

How Marker Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:MRKR Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 245-1050
30 Jun 244-1050
31 Mar 243-1270
31 Dec 233-1470
30 Sep 233-1480
30 Jun 234-17100
31 Mar 234-14100
31 Dec 224-20110
30 Sep 224-26130
30 Jun 223-33130
31 Mar 222-43140
31 Dec 211-42130
30 Sep 210-41120
30 Jun 210-36120
31 Mar 210-31110
31 Dec 200-29100
30 Sep 201-25100
30 Jun 201-23100
31 Mar 200-23100
31 Dec 190-21100
30 Sep 190-152250
30 Jun 190-151270
31 Mar 190-15026-2
31 Dec 180-148240
30 Sep 180-158-4
30 Jun 180-157-2
31 Mar 180-1271
31 Dec 170-1160
30 Sep 170-1064
30 Jun 170-854
31 Mar 170054
31 Dec 160-254
30 Sep 160-363
30 Jun 1602853
31 Mar 160-3852
31 Dec 150-3442
30 Sep 150-3322
30 Jun 150-6331
31 Mar 150-221
31 Dec 140-3130
30 Sep 140-3441
30 Jun 140-3331
31 Mar 140-3521

Quality Earnings: MRKR is currently unprofitable.

Growing Profit Margin: MRKR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MRKR is unprofitable, but has reduced losses over the past 5 years at a rate of 33.4% per year.

Accelerating Growth: Unable to compare MRKR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MRKR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: MRKR has a negative Return on Equity (-129.32%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 23:40
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Marker Therapeutics, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Yun ZhongJanney Montgomery Scott LLC
Aydin HuseynovLadenburg Thalmann & Company